COVID-19 vaccine acceptance over time in patients with immune-mediated inflammatory rheumatic diseases

Laura Boekel; Femke Hooijberg; Yaëlle R. Besten; Erik H. Vogelzang; Maurice Steenhuis; Maureen Leeuw; Sadaf Atiqi; Ronald van Vollenhoven; Willem F. Lems; Wouter H. Bos; Carla A. Wijbrandts; Martijn Gerritsen; Charlotte Krieckaert; Alexandre E. Voskuyl; Irene E. van der Horst-Bruinsma; Sander W. Tas; Maarten Boers; Theo Rispens; Michael T. Nurmohamed; Gertjan Wolbink

doi:10.1016/S2665-9913(22)00009-1

COVID-19 vaccine acceptance over time in patients with immune-mediated inflammatory rheumatic diseases

Laura Boekel, Femke Hooijberg, Yaëlle R. Besten, Erik H. Vogelzang, Maurice Steenhuis, Maureen Leeuw, Sadaf Atiqi, Ronald van Vollenhoven, Willem F. Lems, Wouter H. Bos, Carla A. Wijbrandts, Martijn Gerritsen, Charlotte Krieckaert, Alexandre E. Voskuyl, Irene E. van der Horst-Bruinsma, Sander W. Tas, Maarten Boers, Theo Rispens, Michael T. Nurmohamed, Gertjan Wolbink

Research output: Contribution to journal › Comment/Letter to the editor › Academic

Original language	English
Pages (from-to)	e310-e313
Journal	The Lancet Rheumatology
Volume	4
Issue number	5
DOIs	https://doi.org/10.1016/S2665-9913(22)00009-1
Publication status	Published - 1 May 2022

Access to Document

10.1016/S2665-9913(22)00009-1

Cite this

Boekel, L., Hooijberg, F., Besten, Y. R., Vogelzang, E. H., Steenhuis, M., Leeuw, M., Atiqi, S., van Vollenhoven, R., Lems, W. F., Bos, W. H., Wijbrandts, C. A., Gerritsen, M., Krieckaert, C., Voskuyl, A. E., van der Horst-Bruinsma, I. E., Tas, S. W., Boers, M., Rispens, T., Nurmohamed, M. T., & Wolbink, G. (2022). COVID-19 vaccine acceptance over time in patients with immune-mediated inflammatory rheumatic diseases. The Lancet Rheumatology, 4(5), e310-e313. https://doi.org/10.1016/S2665-9913(22)00009-1

@article{5be54c5436074f2f8d473794c52fdac9,

title = "COVID-19 vaccine acceptance over time in patients with immune-mediated inflammatory rheumatic diseases",

author = "Laura Boekel and Femke Hooijberg and Besten, {Ya{\"e}lle R.} and Vogelzang, {Erik H.} and Maurice Steenhuis and Maureen Leeuw and Sadaf Atiqi and {van Vollenhoven}, Ronald and Lems, {Willem F.} and Bos, {Wouter H.} and Wijbrandts, {Carla A.} and Martijn Gerritsen and Charlotte Krieckaert and Voskuyl, {Alexandre E.} and {van der Horst-Bruinsma}, {Irene E.} and Tas, {Sander W.} and Maarten Boers and Theo Rispens and Nurmohamed, {Michael T.} and Gertjan Wolbink",

note = "Funding Information: Trial ID NL8513 received funding from ZonMw and the Reade Foundation. TR and GW received funding from ZonMw during the conduct of the study. WHB reports grants and personal fees from Abbvie, Eli Lilly, and Sanofi; personal fees from Galapagos; and grants from Gelgene, Pfizer, Roche, and UCB, outside the submitted work. All other authors declare no competing interests.",

year = "2022",

month = may,

day = "1",

doi = "10.1016/S2665-9913(22)00009-1",

language = "English",

volume = "4",

pages = "e310--e313",

journal = "The Lancet Rheumatology",

issn = "2665-9913",

publisher = "Lancet Publishing Group",

number = "5",

}

Boekel, L, Hooijberg, F, Besten, YR, Vogelzang, EH, Steenhuis, M, Leeuw, M , Atiqi, S , van Vollenhoven, R , Lems, WF , Bos, WH, Wijbrandts, CA, Gerritsen, M, Krieckaert, C, Voskuyl, AE , van der Horst-Bruinsma, IE, Tas, SW, Boers, M, Rispens, T, Nurmohamed, MT & Wolbink, G 2022, 'COVID-19 vaccine acceptance over time in patients with immune-mediated inflammatory rheumatic diseases', The Lancet Rheumatology, vol. 4, no. 5, pp. e310-e313. https://doi.org/10.1016/S2665-9913(22)00009-1

TY - JOUR

T1 - COVID-19 vaccine acceptance over time in patients with immune-mediated inflammatory rheumatic diseases

AU - Boekel, Laura

AU - Hooijberg, Femke

AU - Besten, Yaëlle R.

AU - Vogelzang, Erik H.

AU - Steenhuis, Maurice

AU - Leeuw, Maureen

AU - Atiqi, Sadaf

AU - van Vollenhoven, Ronald

AU - Lems, Willem F.

AU - Bos, Wouter H.

AU - Wijbrandts, Carla A.

AU - Gerritsen, Martijn

AU - Krieckaert, Charlotte

AU - Voskuyl, Alexandre E.

AU - van der Horst-Bruinsma, Irene E.

AU - Tas, Sander W.

AU - Boers, Maarten

AU - Rispens, Theo

AU - Nurmohamed, Michael T.

AU - Wolbink, Gertjan

N1 - Funding Information: Trial ID NL8513 received funding from ZonMw and the Reade Foundation. TR and GW received funding from ZonMw during the conduct of the study. WHB reports grants and personal fees from Abbvie, Eli Lilly, and Sanofi; personal fees from Galapagos; and grants from Gelgene, Pfizer, Roche, and UCB, outside the submitted work. All other authors declare no competing interests.

PY - 2022/5/1

Y1 - 2022/5/1

UR - http://www.scopus.com/inward/record.url?scp=85129867073&partnerID=8YFLogxK

U2 - 10.1016/S2665-9913(22)00009-1

DO - 10.1016/S2665-9913(22)00009-1

M3 - Comment/Letter to the editor

C2 - 35156061

SN - 2665-9913

VL - 4

SP - e310-e313

JO - The Lancet Rheumatology

JF - The Lancet Rheumatology

IS - 5

ER -

COVID-19 vaccine acceptance over time in patients with immune-mediated inflammatory rheumatic diseases

Access to Document

Other files and links

Cite this